SARS-CoV-2 Vaccine Responses in Individuals with Antibody Deficiency: Findings from the COV-AD Study

Author:

Shields Adrian M.,Faustini Sian E.,Hill Harriet J.,Al-Taei Saly,Tanner Chloe,Ashford Fiona,Workman Sarita,Moreira Fernando,Verma Nisha,Wagg Hollie,Heritage Gail,Campton Naomi,Stamataki Zania,Klenerman Paul,Thaventhiran James E. D.,Goddard Sarah,Johnston Sarah,Huissoon Aarnoud,Bethune Claire,Elcombe Suzanne,Lowe David M.,Patel Smita Y.,Savic Sinisa,Burns Siobhan O.,Richter Alex G.,Ahmed Zahra,Bancroft Hollie,Bates Michelle,Clifford Hayley,Davis Georgina,Dasgin Joanne,Dinally Mohammad,Dhalla Fatima,Efstathiou Elena,Elkhalifa Shuayb,Gompels Mark,Hartland Dan,Hoque Madeeha,Heritage Emily,Hughes Deborah,Ivory Ann,Jain Rashmi,Kelly Sinead,McCarthy Theresa,McGee Christopher,Mullan Daniel,Morsi Hadeil,O’Grady Eileen,Page Shannon,Peters Nicholas,Plant Timothy,Shajidevadas Archana,Slowinsksa Malgorzata,Suleiman Zehra,Townsend Neil,Trinham Charlotte,Wareham Stuart,Walder Sinead,

Abstract

Abstract Background Vaccination prevents severe morbidity and mortality from COVID-19 in the general population. The immunogenicity and efficacy of SARS-CoV-2 vaccines in patients with antibody deficiency is poorly understood. Objectives COVID-19 in patients with antibody deficiency (COV-AD) is a multi-site UK study that aims to determine the immune response to SARS-CoV-2 infection and vaccination in patients with primary or secondary antibody deficiency, a population that suffers from severe and recurrent infection and does not respond well to vaccination. Methods Individuals on immunoglobulin replacement therapy or with an IgG less than 4 g/L receiving antibiotic prophylaxis were recruited from April 2021. Serological and cellular responses were determined using ELISA, live-virus neutralisation and interferon gamma release assays. SARS-CoV-2 infection and clearance were determined by PCR from serial nasopharyngeal swabs. Results A total of 5.6% (n = 320) of the cohort reported prior SARS-CoV-2 infection, but only 0.3% remained PCR positive on study entry. Seropositivity, following two doses of SARS-CoV-2 vaccination, was 54.8% (n = 168) compared with 100% of healthy controls (n = 205). The magnitude of the antibody response and its neutralising capacity were both significantly reduced compared to controls. Participants vaccinated with the Pfizer/BioNTech vaccine were more likely to be seropositive (65.7% vs. 48.0%, p = 0.03) and have higher antibody levels compared with the AstraZeneca vaccine (IgGAM ratio 3.73 vs. 2.39, p = 0.0003). T cell responses post vaccination was demonstrable in 46.2% of participants and were associated with better antibody responses but there was no difference between the two vaccines. Eleven vaccine-breakthrough infections have occurred to date, 10 of them in recipients of the AstraZeneca vaccine. Conclusion SARS-CoV-2 vaccines demonstrate reduced immunogenicity in patients with antibody deficiency with evidence of vaccine breakthrough infection.

Funder

UK Research and Innovation

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3